4D Molecular Therapeutics' share price fell by over 15% in response to its latest data readout related to Wet-AMD therapy 4D-150. Investors reacted negatively to the news, which may be surprising as ...
In a report released yesterday, Salveen Richter from Goldman Sachs reiterated a Buy rating on 4D Molecular Therapeutics, with a price target of $38.00. The company’s shares closed yesterday at $5.53.
Chardan Capital analyst Geulah Livshits maintained a Buy rating on 4D Molecular Therapeutics yesterday and set a price target of $25.40. The company’s shares closed yesterday at $5.53. Take advantage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback